Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Journal Title: OncoReview - Year 2011, Vol 1, Issue 2
Abstract
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate. We performed a placebo-controlled,double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs. Thehypothesis was that octreotide LAR prolongs time to tumor progression and survival.Patients and Methods: Treatment-naive patients were randomly assigned to either placebo or octreotide LAR 30 mg intramuscularly in monthly intervals until tumor progression or death. The primary efficacy end point was time to tumor progression. Secondary end points were survival time and tumor response. This report is based on 67 tumor progressions and 16 observed deaths in 85 patients at the time of the planned interim analysis.Results: Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR]=0.34; 95% CI, 0.20 to 0.59; P=0,000072). After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group. Functionally active and inactive tumors responded similarly. The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor. Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively. The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).Conclusion: Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs. Because of the low number of observed deaths, survival analysis was not confirmatory.
Authors and Affiliations
Anja Rinke, Hans-Helge Muller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Blaker, Jan Harder, Christian Arnold, Thomas Gress, Rudolf Arnold
Keywords
Related Articles
- EP ID EP53101
- DOI -
- Views 193
- Downloads 0
Wysięk opłucnowy u pacjentki z przewlekłą białaczką szpikową leczonej dazatynibem - opis przypadku
Przewlekła białaczka szpikowa (CML, chronic myeloid leukemia) to nowotwór mieloproliferacyjny z obecnością zaburzeń cytogenetycznych pod postacią translokacji genu ABL z chromosomu 9 na chromosom 22: t(9;22)(q34;q11). Ak...
Nowe spojrzenie na ocenę skuteczności terapii celowanych zaawansowanego raka nerki– kontrowersje
W ciągu ostatnich kilku lat daje się zaobserwować zdecydowany rozwój nowoczesnych terapii stosowanych w leczeniu zaawansowanego/ rozsianego raka nerki, związany przede wszystkim z poznaniem podstaw molekularnych raka ner...
Terapie celowane wysoko zróżnicowanych guzów neuroendokrynnych
Guzy neuroendokrynne (NETs, neuroendocrine tumors) stanowią heterogenną grupę nowotworów o różnej biologii i rokowaniu. Terapia zaawansowanych raków neuroendokrynnych jest ograniczona. Leczenie chirurgiczne, bezpośrednia...
Clinical usefulness of measuring the number of Circulating Tumor Cells (CTC) in breast cancer patients
Background: Monitoring the breast cancer patients after an adjuvant therapy usually involves imaging methods or biopsy. Alternatively, breast cancer markers can be determined – one of them is the number of circulating tu...
Powikłania zakrzepowo-zatorowe podczas hormonoterapii raka piersi - opis przypadku
69-letnia otyła kobieta po przebytej mastektomii lewostronnej i operacji oszczędzającej prawej piersi z powodu raka piersi, po przebytej chemio- i radioterapii, w trakcie uzupełniającej hormonoterapii przy użyciu tamoksy...